The transistor technology developer has disclosed $21.8m in series A funding from investors including Agilent Technologies across three tranches.
US-based graphene transistor technology developer Cardea Bio has added $6.5m to a series A round featuring laboratory instrument producer Agilent Technologies now sized at more than $20m.
Healthcare-focused investment fund 3E Bioventures Capital led the $6.5m tranche, participating alongside undisclosed existing investors
Founded in 2013, Cardea Bio has developed graphene-based transistor technology which can integrate biology into electronics for purposes such as DNA testing, viral detection and molecular analysis.
The company received $7.8m in a March 2019 series A-1…
